Potential use of nanomedicine for the anti-inflammatory treatment of neurodegenerative diseases

Current Pharmaceutical Design

Volumn 24, Issue 14, 2018, Pages 1589-1616

  Cayero Otero, María Dolores ^a   Espinosa Oliva, Ana M ^a   Herrera, Antonio J ^a   García Domínguez, Irene ^a   Fernández Arévalo, Mercedes ^a   Martín Banderas, Lucía ^a   de Pablos, Rocío M ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Alzheimer s disease; Anti inflammatory drugs; Nanoparticles; Neuroinflammation; Nose to brain; Parkinson s disease; PLGA

Indexed keywords

ACETYLSALICYLIC ACID; ADENO ASSOCIATED VIRUS VECTOR; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ANTHOCYANIN; APIGENIN; APOCYNIN; AURAPTENE; BAICALEIN; BROMISOVAL; CASPASE 8; CLOZAPINE; CORTICOSTEROID; DEXMEDETOMIDINE; ECHINACEA PURPUREA EXTRACT; FERULIC ACID; GALANGIN; GALECTIN 3; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; POLYGLACTIN; PROPOFOL; RESVERATROL; SINOMENINE; TAU PROTEIN; TRIPTOLIDE; UNINDEXED DRUG; VANILLIN; VIRUS VECTOR; WOGONIN; ANTIINFLAMMATORY AGENT; NANOPARTICLE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BLEEDING; BLOOD BRAIN BARRIER; BRAIN REGION; CARDIOVASCULAR DISEASE; CELL ACTIVATION; DEGENERATIVE DISEASE; DIGESTIVE SYSTEM ULCER; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MICROGLIA; NANOMEDICINE; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; THERMODYNAMICS; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CHEMISTRY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEURODEGENERATIVE DISEASES; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

EID: 85050202695     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612824666180403113015     Document Type: Review

References (400)

1. Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet 2017; 389(10076): 1323-35.
2. Tam VH, Sosa C, Liu R, Yao N, Priestley RD. Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier. Int J Pharm 2016; 515(1-2): 331-42.
3. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 2007; 59(6): 454-77.
4. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release 2016; 235: 34-47.
5. Cekanaviciute E, Buckwalter MS. Astrocytes: Integrative regulators of neuroinflammation in stroke and other neurological diseases. Neurotherapeutics 2016; 13(4): 685-701.
6. Colombo E, Farina C. Astrocytes: Key regulators of neuroinflammation. Trends Immunol 2016; 37(9): 608-20.
7. Steardo L Jr, Bronzuoli MR, Iacomino A, Esposito G, Steardo L, Scuderi C. Does neuroinflammation turn on the flame in Alzheimer’s disease? Focus on astrocytes. Front Neurosci 2015; 9: 259.
8. Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol 2017; 35: 441-68.
9. Piirainen S, Youssef A, Song C, et al. Psychosocial stress on neuroinflammation and cognitive dysfunctions in Alzheimer’s disease: the emerging role for microglia? Neurosci Biobehav Rev 2017; 77: 148-64.
10. Akiyama H, McGeer PL. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res 1989; 489(2): 247-53.
11. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 1988; 38(8): 1285-91.
12. Bolós M, Perea JR, Avila J. Alzheimer’s disease as an inflammatory disease. Biomol Concepts 2017; 8(1): 37-43.
13. Bronzuoli MR, Iacomino A, Steardo L, Scuderi C. Targeting neuroinflammation in Alzheimer’s disease. J Inflamm Res 2016; 9: 199-208.
14. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015; 14(4): 388-405.
15. De Virgilio A, Greco A, Fabbrini G, et al. Parkinson’s disease: Autoimmunity and neuroinflammation. Autoimmun Rev 2016; 15(10): 1005-11.
16. Manocha GD, Floden AM, Puig KL, Nagamoto-Combs K, Scherzer CR, Combs CK. Defining the contribution of neuroinflammation to Parkinson’s disease in humanized immune system mice. Mol Neurodegener 2017; 12(1): 17.
17. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 1991; 12(10): 383-8.
18. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297(5580): 353-6.
19. Hardy JA, Higgins GA. Alzheimer’s disease: The amyloid cascade hypothesis. Science 1992; 256(5054): 184-5.
20. Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120(3): 885-90.
21. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solane-zumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014; 370(4): 311-21.
22. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bap-ineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014; 370(4): 322-33.
23. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol 2010; 45(1): 30-40.
24. Wang L, Benzinger TL, Su Y, et al. Evaluation of tau imaging in staging alzheimer disease and revealing interactions between β-amyloid and tauopathy. JAMA Neurol 2016; 73(9): 1070-7.
25. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82(4): 239-59.
26. Matsuoka Y, Picciano M, Malester B, et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer’s disease. Am J Pathol 2001; 158(4): 1345-54.
27. Wirz KT, Bossers K, Stargardt A, et al. Cortical beta amyloid protein triggers an immune response, but no synaptic changes in the APPswe/PS1dE9 Alzheimer’s disease mouse model. Neurobiol Aging 2013; 34(5): 1328-42.
28. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 2003; 23(7): 2665-74.
29. Liu Y, Walter S, Stagi M, et al. LPS receptor (CD14): A receptor for phagocytosis of Alzheimer’s amyloid peptide. Brain 2005; 128(Pt 8): 1778-89.
30. Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer’s disease amyloid beta-protein via a scavenger receptor. Neuron 1996; 17(3): 553-65.
31. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11(2): 155-61.
32. Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 2013; 14(8): 812-20.
33. Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Po-cock JM. Microglial genes regulating neuroinflammation in the progression of Alzheimer’s disease. Curr Opin Neurobiol 2016; 36: 74-81.
34. Ferretti MT, Cuello AC. Does a pro-inflammatory process precede Alzheimer’s disease and mild cognitive impairment? Curr Alzheimer Res 2011; 8(2): 164-74.
35. Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell 2013; 153(3): 707-20.
36. Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol 2009; 118(4): 475-85.
37. Keren-Shaul H, Spinrad A, Weiner A, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell 2017; 169: 1276-90 e17.
38. Tanzi RE. TREM2 and risk of Alzheimer’s disease--friend or foe? N Engl J Med 2015; 372(26): 2564-5.
39. Walter J. The triggering receptor expressed on myeloid cells 2: A molecular link of neuroinflammation and neurodegenerative diseases. J Biol Chem 2016; 291(9): 4334-41.
40. Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119(1): 182-92.
41. Dzamko N, Gysbers A, Perera G, et al. Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol 2017; 133(2): 303-19.
42. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 2006; 21(2): 404-12.
43. Humbert-Claude M, Duc D, Dwir D, et al. Tollip, an early regulator of the acute inflammatory response in the substantia nigra. J Neuroinflammation 2016; 13(1): 303.
44. Saunders JA, Estes KA, Kosloski LM, et al. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson’s disease. J Neuroimmune Pharmacol 2012; 7(4): 927-38.
45. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007; 208(1): 1-25.
46. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388(6645): 839-40.
47. Javed H, Kamal MA, Ojha S. An overview on the role of α-synuclein in experimental models of parkinson’s disease from pathogenesis to therapeutics. CNS Neurol Disord Drug Targets 2016; 15(10): 1240-52.
48. Marmion DJ, Kordower JH. alpha-Synuclein nonhuman primate models of Parkinson’s disease. J Neural Transm (Vienna) 2017.
49. Visanji NP, Brotchie JM, Kalia LV, et al. α-synuclein-based animal models of Parkinson’s disease: Challenges and opportunities in a new era. Trends Neurosci 2016; 39(11): 750-62.
50. Yamada T, McGeer PL, McGeer EG. Lewy bodies in Parkinson’s disease are recognized by antibodies to complement proteins. Acta Neuropathol 1992; 84(1): 100-4.
51. Fellner L, Irschick R, Schanda K, et al. Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia 2013; 61(3): 349-60.
52. Kim C, Ho DH, Suk JE, et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 2013; 4: 1562.
53. Béraud D, Twomey M, Bloom B, et al. α-synuclein alters toll-like receptor Expression. Front Neurosci 2011; 5: 80.
54. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. Toll-like receptors in neurodegeneration. Brain Res Brain Res Rev 2009; 59(2): 278-92.
55. Rojanathammanee L, Murphy EJ, Combs CK. Expression of mutant alpha-synuclein modulates microglial phenotype in vitro. J Neuroinflammation 2011; 8: 44.
56. Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: A process leading to disease progression in Parkinson’s disease. FASEB J 2005; 19(6): 533-42.
57. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener 2015; 4: 19.
58. Gomez-Nicola D, Perry VH. Microglial dynamics and role in the healthy and diseased brain: A paradigm of functional plasticity. Neuroscientist 2015; 21(2): 169-84.
59. Perry VH. Microglia. Microbiol Spectr 2015; 4.
60. McDade E, Bateman RJ. Stop Alzheimer’s before it starts. Nature 2017; 547(7662): 153-5.
61. Bagyinszky E, Giau VV, Shim K, Suk K, An SSA, Kim S. Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis. J Neurol Sci 2017; 376: 242-54.
62. Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev 2012; (2): CD006378.
63. Rees K, Stowe R, Patel S, et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies. Cochrane Database Syst Rev 2011; (11): CD008454.
64. Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer’s disease patients. Cochrane Database Syst Rev 2002; (2): CD003673.
65. Tabet N, Feldmand H. Ibuprofen for Alzheimer’s disease. Cochrane Database Syst Rev 2003; (2): CD004031.
66. Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-21.
67. McGeer PL, McGeer EG. Anti-inflammatory drugs in the fight against Alzheimer’s disease. Ann N Y Acad Sci 1996; 777: 213-20.
68. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997; 48(3): 626-32.
69. Chen J, Sun Z, Jin M, et al. Inhibition of AGEs/RAGE/Rho/ROCK pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-κB pathway. J Neuroimmunol 2017; 305: 108-14.
70. Roser AE, Tönges L, Lingor P. Modulation of microglial activity by rho-kinase (ROCK) inhibition as therapeutic strategy in parkinson’s disease and amyotrophic lateral sclerosis. Front Aging Neurosci 2017; 9: 94.
71. Wang JY, Wen LL, Huang YN, Chen YT, Ku MC. Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr Pharm Des 2006; 12(27): 3521-33.
72. Block ML. NADPH oxidase as a therapeutic target in Alzheimer’s disease. BMC Neurosci 2008; 9(Suppl. 2): S8.
73. Nam KN, Koketsu M, Lee EH. 5-Chloroacetyl-2-amino-1,3-selenazoles attenuate microglial inflammatory responses through NF-kappaB inhibition. Eur J Pharmacol 2008; 589(1-3): 53-7.
74. Jeohn GH, Cooper CL, Jang KJ, Kim HC, Hong JS. Gö6976 protects mesencephalic neurons from lipopolysaccharide-elicited death by inhibiting p38 MAP kinase phosphorylation. Ann N Y Acad Sci 2002; 962: 347-59.
75. Jeohn GH, Cooper CL, Jang KJ, et al. Gö6976 inhibits LPS-induced microglial TNFalpha release by suppressing p38 MAP kinase activation. Neuroscience 2002; 114(3): 689-97.
76. Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 2011; 63(3): 471-538.
77. Yang W, Yan A, Zhang T, et al. Thromboxane A2 Receptor Stimulation Enhances Microglial Interleukin-1β and NO Biosynthesis Mediated by the Activation of ERK Pathway. Front Aging Neurosci 2016; 8: 8.
78. Chen X, Liu Z, Cao BB, Qiu YH, Peng YP. TGF-β1 Neuroprotection via Inhibition of Microglial Activation in a Rat Model of Parkinson’s Disease. J Neuroimmune Pharmacol 2017; 12(3): 433-46.
79. Lee EJ, Woo MS, Moon PG, et al. Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 2010; 185(1): 615-23.
80. Lee EJ, Kim HS. Inhibitory mechanism of MMP-9 gene expression by ethyl pyruvate in lipopolysaccharide-stimulated BV2 microglial cells. Neurosci Lett 2011; 493(1-2): 38-43.
81. Lee EJ, Kim HS. The anti-inflammatory role of tissue inhibitor of metalloproteinase-2 in lipopolysaccharide-stimulated microglia. J Neuroinflammation 2014; 11: 116.
82. Lee EJ, Moon PG, Baek MC, Kim HS. Comparison of the effects of matrix metalloproteinase inhibitors on TNF-α release from activated microglia and TNF-α converting enzyme activity. Biomol Ther (Seoul) 2014; 22(5): 414-9.
83. Shi F, Duan S, Cui J, et al. Induction of matrix metalloproteinase-3 (MMP-3) expression in the microglia by lipopolysaccharide (LPS) via upregulation of glycoprotein nonmetastatic melanoma B (GPNMB) expression. J Mol Neurosci 2014; 54(2): 234-42.
84. Woo MS, Park JS, Choi IY, Kim WK, Kim HS. Inhibition of MMP-3 or-9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J Neurochem 2008; 106(2): 770-80.
85. Hur J, Lee P, Kim MJ, Cho YW. Regulatory effect of 25-hydroxyvitamin D3 on nitric oxide production in activated microglia. Korean J Physiol Pharmacol 2014; 18(5): 397-402.
86. Nallathamby N, Guan-Serm L, Vidyadaran S, Abd Malek SN, Raman J, Sabaratnam V. Ergosterol of Cordyceps militaris Attenuates LPS Induced Inflammation in BV2 Microglia Cells. Nat Prod Commun 2015; 10(6): 885-6.
87. Raha S, Lee HJ, Yumnam S, et al. Vitamin D2 suppresses amyloid-β 25-35 induced microglial activation in BV2 cells by blocking the NF-κB inflammatory signaling pathway. Life Sci 2016; 161: 37-44.
88. Eyles D, Almeras L, Benech P, et al. Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain. J Steroid Biochem Mol Biol 2007; 103(3-5): 538-45.
89. McGrath J. Does ‘imprinting’ with low prenatal vitamin D contribute to the risk of various adult disorders? Med Hypotheses 2001; 56(3): 367-71.
90. Schaufelberger SA, Rosselli M, Barchiesi F, Gillespie DG, Jackson EK, Dubey RK. 2-Methoxyestradiol, an endogenous 17β-estradiol metabolite, inhibits microglial proliferation and activation via an estrogen receptor-independent mechanism. Am J Physiol Endocrinol Metab 2016; 310(5): E313-22.
91. Shah SA, Khan M, Jo MH, Jo MG, Amin FU, Kim MO. Melatonin stimulates the SIRT1/Nrf2 signaling pathway counteracting Lipopolysaccharide (LPS)-induced oxidative stress to rescue postnatal rat brain. CNS Neurosci Ther 2017; 23(1): 33-44.
92. Pearse DD, Hughes ZA. PDE4B as a microglia target to reduce neuroinflammation. Glia 2016; 64(10): 1698-709.
93. You T, Cheng Y, Zhong J, et al. Roflupram, a Phosphodiesterase 4 Inhibitior, Suppresses Inflammasome Activation through Autophagy in Microglial Cells. ACS Chem Neurosci 2017; 8(11): 2381-92.
94. Chen PS, Wang CC, Bortner CD, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007; 149(1): 203-12.
95. Qu WS, Liu JL, Li CY, et al. Rapidly activated epidermal growth factor receptor mediates lipopolysaccharide-triggered migration of microglia. Neurochem Int 2015; 90: 85-92.
96. Martínez-Zamudio RI, Ha HC. PARP1 enhances inflammatory cytokine expression by alteration of promoter chromatin structure in microglia. Brain Behav 2014; 4(4): 552-65.
97. Wang B, Zhang Y, Cao W, Wei X, Chen J, Ying W. SIRT2 Plays Significant Roles in Lipopolysaccharides-Induced Neuroinflammation and Brain Injury in Mice. Neurochem Res 2016; 41(9): 2490-500.
98. Chen H, Wu D, Ding X, Ying W. SIRT2 is required for lipopolysaccharide-induced activation of BV2 microglia. Neuroreport 2015; 26(2): 88-93.
99. Voisin MB, Nourshargh S. Neutrophil transmigration: emergence of an adhesive cascade within venular walls. J Innate Immun 2013; 5(4): 336-47.
100. Becchi S, Buson A, Foot J, Jarolimek W, Balleine BW. Inhibition of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 reduces lipopolysaccharide-induced neuroinflammation. Br J Pharmacol 2017; 174(14): 2302-17.
101. Choi DK, Koppula S, Suk K. Inhibitors of microglial neurotoxicity: focus on natural products. Molecules 2011; 16(2): 1021-43.
102. Jung WK, Ahn YW, Lee SH, et al. Ecklonia cava ethanolic extracts inhibit lipopolysaccharide-induced cyclooxygenase-2 and inducible nitric oxide synthase expression in BV2 microglia via the MAP kinase and NF-kappaB pathways. Food Chem Toxicol 2009; 47(2): 410-7.
103. Kim AR, Lee B, Joung EJ, et al. 6,6′-Bieckol suppresses inflammatory responses by down-regulating nuclear factor-κB activation via Akt, JNK, and p38 MAPK in LPS-stimulated microglial cells. Immunopharmacol Immunotoxicol 2016; 38(3): 244-52.
104. Nam KN, Park YM, Jung HJ, et al. Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol 2010; 648(1-3): 110-6.
105. Jung HW, Son HY, Minh CV, Kim YH, Park YK. Methanol extract of Ficus leaf inhibits the production of nitric oxide and proinflammatory cytokines in LPS-stimulated microglia via the MAPK pathway. Phytother Res 2008; 22(8): 1064-9.
106. Moon DO, Choi YH, Kim ND, Park YM, Kim GY. Anti-inflammatory effects of beta-lapachone in lipopolysaccharide-stimulated BV2 microglia. Int Immunopharmacol 2007; 7(4): 506-14.
107. Chan CK, Tan LT, Andy SN, Kamarudin MNA, Goh BH, Kadir HA. Anti-neuroinflammatory Activity ofElephantopus scaberL. via Activation of Nrf2/HO-1 Signaling and Inhibition of p38 MAPK Pathway in LPS-Induced Microglia BV-2 Cells. Front Pharmacol 2017; 8: 397.
108. Cui Y, Wu J, Jung SC, et al. Neuroprotective effect of methyl lucidone against microglia-mediated neurotoxicity. Eur J Pharmacol 2012; 690(1-3): 4-12.
109. 2-terminal kinase and p38 mitogen-activated protein kinase pathway in activated microglial cells. J Pharmacol Sci 2011; 116(3): 296-308.
110. Kang BK, Kim MK, Kim SY, et al. Anti-Neuroinflammatory Effects of Uncaria sinensis in LPS-Stimulated BV2 Microglia Cells and Focal Cerebral Ischemic Mice. Am J Chin Med 2015; 43(6): 1099-115.
111. Oh YT, Lee JY, Lee J, et al. Oleamide suppresses lipopolysaccharide-induced expression of iNOS and COX-2 through inhibition of NF-kappaB activation in BV2 murine microglial cells. Neurosci Lett 2010; 474(3): 148-53.
112. Dilshara MG, Lee KT, Lee CM, et al. New compound, 5-O-isoferuloyl-2-deoxy-D-ribono-γ-lacton from Clematis mandshurica: Anti-inflammatory effects in lipopolysaccharide-stimulated BV2 microglial cells. Int Immunopharmacol 2015; 24(1): 14-23.
113. Han Q, Yuan Q, Meng X, Huo J, Bao Y, Xie G. 6-Shogaol attenuates LPS-induced inflammation in BV2 microglia cells by activating PPAR-γ. Oncotarget 2017; 8(26): 42001-6.
114. Eom HW, Park SY, Kim YH, et al. Bambusae Caulis in Taeniam modulates neuroprotective and anti-neuroinflammatory effects in hippocampal and microglial cells via HO-1-and Nrf-2-mediated pathways. Int J Mol Med 2012; 30(6): 1512-20.
115. Cheong MH, Lee SR, Yoo HS, et al. Anti-inflammatory effects of Polygala tenuifolia root through inhibition of NF-κB activation in lipopolysaccharide-induced BV2 microglial cells. J Ethnopharmacol 2011; 137(3): 1402-8.
116. Shi TX, Wang S, Zeng KW, Tu PF, Jiang Y. Inhibitory constituents from the aerial parts of Polygala tenuifolia on LPS-induced NO production in BV2 microglia cells. Bioorg Med Chem Lett 2013; 23(21): 5904-8.
117. Mana L, Wang S, Zhu H, et al. Qingkailing Suppresses the Activation of BV2 Microglial Cells by Inhibiting Hy-poxia/Reoxygenation-Induced Inflammatory Responses. Evid Based Complement Alternat Med 2014; 2014: 696218.
118. Li J, Zhang S, Lu M, et al. Hydroxysafflor yellow A suppresses inflammatory responses of BV2 microglia after oxygen-glucose deprivation. Neurosci Lett 2013; 535: 51-6.
119. Zhang Z, Wu Z, Zhu X, Hui X, Pan J, Xu Y. Hydroxy-safflor yellow A inhibits neuroinflammation mediated by Abeta(1)(-)(4)(2) in BV-2 cells. Neurosci Lett 2014; 562: 39-44.
120. Jeong YH, Jung JS, Le TK, Kim DH, Kim HS. Lancemaside A inhibits microglial activation via modulation of JNK signaling pathway. Biochem Biophys Res Commun 2013; 431(3): 369-75.
121. Zhang F, Wang YY, Yang J, Lu YF, Liu J, Shi JS. Tetrahydroxys-tilbene glucoside attenuates neuroinflammation through the inhibition of microglia activation. Oxid Med Cell Longev 2013; 2013: 680545.
122. Moon YJ, Lee JY, Oh MS, et al. Inhibition of inflammation and oxidative stress by Angelica dahuricae radix extract decreases apoptotic cell death and improves functional recovery after spinal cord injury. J Neurosci Res 2012; 90(1): 243-56.
123. Park YK, Chung YS, Kim YS, Kwon OY, Joh TH. Inhibition of gene expression and production of iNOS and TNF-alpha in LPS-stimulated microglia by methanol extract of Phellodendri cortex. Int Immunopharmacol 2007; 7(7): 955-62.
124. Kim HG, Kim JY, Whang WW, Oh MS. Neuroprotective effect of Chunghyuldan from amyloid beta oligomer induced neuroinflammation in vitro and in vivo. Can J Physiol Pharmacol 2014; 92(6): 429-37.
125. Jung HW, Yoon CH, Park KM, Han HS, Park YK. Hexane fraction of Zingiberis Rhizoma Crudus extract inhibits the production of nitric oxide and proinflammatory cytokines in LPS-stimulated BV2 microglial cells via the NF-kappaB pathway. Food Chem Toxicol 2009; 47(6): 1190-7.
126. Wan W, Zhang C, Danielsen M, et al. EGb761 improves cognitive function and regulates inflammatory responses in the APP/PS1 mouse. Exp Gerontol 2016; 81: 92-100.
127. Liu Y, Chen HL, Yang G. Extract of Tripterygium wilfordii Hook F protect dopaminergic neurons against lipopolysaccharide-induced inflammatory damage. Am J Chin Med 2010; 38(4): 801-14.
128. Pan XD, Chen XC, Zhu YG, et al. Neuroprotective role of trip-chlorolide on inflammatory neurotoxicity induced by lipopolysaccharide-activated microglia. Biochem Pharmacol 2008; 76(3): 362-72.
129. Jung KH, Kim MJ, Ha E, et al. Suppressive effect of Punica granatum on the production of tumor necrosis factor (Tnf) in BV2 microglial cells. Biol Pharm Bull 2006; 29(6): 1258-61.
130. Hou RC, Chen HL, Tzen JT, Jeng KC. Effect of sesame antioxidants on LPS-induced NO production by BV2 microglial cells. Neuroreport 2003; 14(14): 1815-9.
131. Hou RC, Chen YS, Chen CH, Chen YH, Jeng KC. Protective effect of 1,2,4-benzenetriol on LPS-induced NO production by BV2 microglial cells. J Biomed Sci 2006; 13(1): 89-99.
132. Kang CH, Jayasooriya RG, Dilshara MG, et al. Caffeine suppresses lipopolysaccharide-stimulated BV2 microglial cells by suppressing Akt-mediated NF-κB activation and ERK phosphorylation. Food Chem Toxicol 2012; 50(12): 4270-6.
133. Yan X, Liu DF, Zhang XY, et al. Vanillin Protects Dopaminergic Neurons against Inflammation-Mediated Cell Death by Inhibiting ERK1/2, P38 and the NF-κB Signaling Pathway. Int J Mol Sci 2017; 18(2): 18.
134. Ho SC, Su MS. Evaluating the anti-neuroinflammatory capacity of raw and steamed garlic as well as five organosulfur compounds. Molecules 2014; 19(11): 17697-714.
135. Park HY, Kim ND, Kim GY, et al. Inhibitory effects of diallyl disulfide on the production of inflammatory mediators and cytokines in lipopolysaccharide-activated BV2 microglia. Toxicol Appl Pharmacol 2012; 262(2): 177-84.
136. Eun CS, Lim JS, Lee J, Lee SP, Yang SA. The protective effect of fermented Curcuma longa L. on memory dysfunction in oxidative stress-induced C6 gliomal cells, proinflammatory-activated BV2 microglial cells, and scopolamine-induced amnesia model in mice. BMC Complement Altern Med 2017; 17(1): 367.
137. Lim SY, Subedi L, Shin D, Kim CS, Lee KR, Kim SY. A New Neolignan Derivative, Balanophonin Isolated fromFirmiana sim-plexDelays the Progress of Neuronal Cell Death by Inhibiting Microglial Activation. Biomol Ther (Seoul) 2017; 25(5): 519-27.
138. Teponno RB, Kusari S, Spiteller M. Recent advances in research on lignans and neolignans. Nat Prod Rep 2016; 33(9): 1044-92.
139. Liu N, Zheng JX, Zhuang YS, Zhou ZK, Zhao JH, Yang L. Anti-Inflammatory Effects of Schisandrin B on LPS-Stimulated BV2 Microglia via Activating PPAR-γ. Inflammation 2017; 40(3): 1006-11.
140. Xu P, Huang MW, Xiao CX, et al. Matairesinol Suppresses Neuroinflammation and Migration Associated with Src and ERK1/2-NF-κB Pathway in Activating BV2 Microglia. Neurochem Res 2017; 42(10): 2850-60.
141. Chen CC, Lin JT, Cheng YF, et al. Amelioration of LPS-induced inflammation response in microglia by AMPK activation. BioMed Res Int 2014; 2014: 692061.
142. Cho N, Moon EH, Kim HW, Hong J, Beutler JA, Sung SH. Inhibition of Nitric Oxide Production in BV2 Microglial Cells by Triter-penes from Tetrapanax papyriferus. Molecules 2016; 21(4): 459.
143. Choi Y, Lee MK, Lim SY, Sung SH, Kim YC. Inhibition of inducible NO synthase, cyclooxygenase-2 and interleukin-1beta by to-rilin is mediated by mitogen-activated protein kinases in microglial BV2 cells. Br J Pharmacol 2009; 156(6): 933-40.
144. Guo K, Mou X, Huang J, Xiong N, Li H. Trans-caryophyllene suppresses hypoxia-induced neuroinflammatory responses by inhibiting NF-κB activation in microglia. J Mol Neurosci 2014; 54(1): 41-8.
145. Rayan NA, Baby N, Pitchai D, et al. Costunolide inhibits proinflammatory cytokines and iNOS in activated murine BV2 microglia. Front Biosci (Elite Ed) 2011; 3: 1079-91.
146. Shi D, Song X, Guo Y, et al. Alismol, a Sesquiterpenoid Isolated from Vladimiria souliei, Suppresses Proinflammatory Mediators in Lipopolysaccharide-Stimulated Microglia. J Mol Neurosci 2017; 62(1): 106-13.
147. Wang H, Liu Y, Zhang J, et al. 15-O-Acetyl-3-O-benzoylcharaciol and helioscopinolide A, two diterpenes isolated from Euphorbia he-lioscopia suppress microglia activation. Neurosci Lett 2016; 612: 149-54.
148. Jung JS, Kim DH, Kim HS. Ginsenoside Rh1 suppresses inducible nitric oxide synthase gene expression in IFN-gamma-stimulated microglia via modulation of JAK/STAT and ERK signaling pathways. Biochem Biophys Res Commun 2010; 397(2): 323-8.
149. Brandenburg LO, Kipp M, Lucius R, Pufe T, Wruck CJ. Sulforaphane suppresses LPS-induced inflammation in primary rat microglia. Inflamm Res 2010; 59(6): 443-50.
150. Wang Y, Zhao H, Lin C, Ren J, Zhang S, Forsythiaside A. Forsythiaside A Exhibits Anti-inflammatory Effects in LPS-Stimulated BV2 Microglia Cells Through Activation of Nrf2/HO-1 Signaling Pathway. Neurochem Res 2016; 41(4): 659-65.
151. Fan B, Dun SH, Gu JQ, Guo Y, Ikuyama S. Pycnogenol Attenuates the Release of Proinflammatory Cytokines and Expression of Per-ilipin 2 in Lipopolysaccharide-Stimulated Microglia in Part via Inhibition of NF-κB and AP-1 Activation. PLoS One 2015; 10(9): e0137837.
152. Zhu MD, Zhao LX, Wang XT, Gao YJ, Zhang ZJ. Ligustilide inhibits microglia-mediated proinflammatory cytokines production and inflammatory pain. Brain Res Bull 2014; 109: 54-60.
153. Hwang KY, Oh YT, Yoon H, et al. Baicalein suppresses hypoxia-induced HIF-1alpha protein accumulation and activation through inhibition of reactive oxygen species and PI 3-kinase/Akt pathway in BV2 murine microglial cells. Neurosci Lett 2008; 444(3): 264-9.
154. Xiong J, Wang C, Chen H, et al. Aβ-induced microglial cell activation is inhibited by baicalin through the JAK2/STAT3 signaling pathway. Int J Neurosci 2014; 124(8): 609-20.
155. Xu J, Zhang Y, Xiao Y, et al. Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPARβ/δ: A potential therapeutic role for CNS autoimmune disease. Cell Death Dis 2013; 4: e569.
156. Chow YL, Lee KH, Vidyadaran S, et al. Cardamonin from Alpinia rafflesiana inhibits inflammatory responses in IFN-γ/LPS-stimulated BV2 microglia via NF-κB signalling pathway. Int Immunopharmacol 2012; 12(4): 657-65.
157. Kim MJ, Seong AR, Yoo JY, et al. Gallic acid, a histone acetyltransferase inhibitor, suppresses β-amyloid neurotoxicity by inhibiting microglial-mediated neuroinflammation. Mol Nutr Food Res 2011; 55(12): 1798-808.
158. Jayasooriya RG, Lee KT, Choi YH, Moon SK, Kim WJ, Kim GY. Antagonistic effects of acetylshikonin on LPS-induced NO and PGE2 production in BV2 microglial cells via inhibition of ROS/PI3K/Akt-mediated NF-κB signaling and activation of Nrf2-dependent HO-1. In Vitro Cell Dev Biol Anim 2015; 51(9): 975-86.
159. Velagapudi R, Kumar A, Bhatia HS, et al. Inhibition of neuroinflammation by thymoquinone requires activation of Nrf2/ARE signalling. Int Immunopharmacol 2017; 48: 17-29.
160. Taka E, Mazzio EA, Goodman CB, et al. Anti-inflammatory effects of thymoquinone in activated BV-2 microglial cells. J Neuroimmunol 2015; 286: 5-12.
161. Wang Y, Gao H, Zhang W, Zhang W, Fang L. Thymoquinone inhibits lipopolysaccharide-induced inflammatory mediators in BV2 microglial cells. Int Immunopharmacol 2015; 26(1): 169-73.
162. Chae U, Min JS, Lee H, et al. Chrysophanol suppresses proinflammatory response in microglia via regulation of Drp1-dependent mitochondrial fission. Immunopharmacol Immunotoxicol 2017; 39(5): 268-75.
163. Hou Y, Li G, Wang J, et al. Okanin, effective constituent of the flower tea Coreopsis tinctoria, attenuates LPS-induced microglial activation through inhibition of the TLR4/NF-κB signaling pathways. Sci Rep 2017; 7: 45705.
164. Choi MJ, Lee EJ, Park JS, Kim SN, Park EM, Kim HS. Anti-inflammatory mechanism of galangin in lipopolysaccharide-stimulated microglia: Critical role of PPAR-γ signaling pathway. Biochem Pharmacol 2017; 144: 120-31.
165. Dilshara MG, Jayasooriya RG, Lee S, Choi YH, Kim GY. Morin downregulates nitric oxide and prostaglandin E2 production in LPS-stimulated BV2 microglial cells by suppressing NF-κB activity and activating HO-1 induction. Environ Toxicol Pharmacol 2016; 44: 62-8.
166. Onasanwo SA, Velagapudi R, El-Bakoush A, Olajide OA. Inhibition of neuroinflammation in BV2 microglia by the biflavonoid ko-laviron is dependent on the Nrf2/ARE antioxidant protective mechanism. Mol Cell Biochem 2016; 414(1-2): 23-36.
167. Wu WY, Wu YY, Huang H, et al. Biochanin A attenuates LPS-induced pro-inflammatory responses and inhibits the activation of the MAPK pathway in BV2 microglial cells. Int J Mol Med 2015; 35(2): 391-8.
168. Zhu LH, Bi W, Qi RB, Wang HD, Lu DX. Luteolin inhibits microglial inflammation and improves neuron survival against inflammation. Int J Neurosci 2011; 121(6): 329-36.
169. Chao CL, Weng CS, Chang NC, Lin JS, Kao ST, Ho FM. Narin-genin more effectively inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in macrophages than in microglia. Nutr Res 2010; 30(12): 858-64.
170. Gresa-Arribas N, Serratosa J, Saura J, Solà C. Inhibition of CCAAT/enhancer binding protein δ expression by chrysin in microglial cells results in anti-inflammatory and neuroprotective effects. J Neurochem 2010; 115(2): 526-36.
171. Zheng LT, Ock J, Kwon BM, Suk K. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. Int Immunopharmacol 2008; 8(3): 484-94.
172. Nam Y, Choi M, Hwang H, et al. Natural flavone jaceosidin is a neuroinflammation inhibitor. Phytother Res 2013; 27(3): 404-11.
173. Wang J, Chen L, Liang Z, et al. Genipin inhibits LPS-induced inflammatory response in BV2 microglial cells. Neurochem Res 2017; 42(10): 2769-76.
174. Yeh CH, Shih HC, Hong HM, et al. Protective effect of wogonin on proinflammatory cytokine generation via Jak1/3-STAT1/3 pathway in lipopolysaccharide stimulated BV2 microglial cells. Toxicol Ind Health 2015; 31(10): 960-6.
175. Yeh CH, Yang ML, Lee CY, et al. Wogonin attenuates endotoxin-induced prostaglandin E2 and nitric oxide production via Src-ERK1/2-NFκB pathway in BV-2 microglial cells. Environ Toxicol 2014; 29(10): 1162-70.
176. He FQ, Qiu BY, Li TK, et al. Tetrandrine suppresses amyloid-β-induced inflammatory cytokines by inhibiting NF-κB pathway in murine BV2 microglial cells. Int Immunopharmacol 2011; 11(9): 1220-5.
177. Leonoudakis D, Rane A, Angeli S, Lithgow GJ, Andersen JK, Chinta SJ. Anti-Inflammatory and Neuroprotective Role of Natural Product Securinine in Activated Glial Cells: Implications for Parkinson’s Disease. Mediators Inflamm 2017; 2017: 8302636.
178. Wang-Sheng C, Jie A, Jian-Jun L, Lan H, Zeng-Bao X, Chang-Qing L. Piperine attenuates lipopolysaccharide (LPS)-induced inflammatory responses in BV2 microglia. Int Immunopharmacol 2017; 42: 44-8.
179. Ding F, Li Y, Hou X, Zhang R, Hu S, Wang Y. Oxymatrine inhibits microglia activation via HSP60-TLR4 signaling. Biomed Rep 2016; 5(5): 623-8.
180. Dong XQ, Du Q, Yu WH, et al. Anti-inflammatory Effects of Oxymatrine Through Inhibition of Nuclear Factor-kappa B and Mitogen-activated Protein Kinase Activation in Lipopolysaccharide-induced BV2 Microglia Cells. Iran J Pharm Res 2013; 12(1): 165-74.
181. Jia L, Liu J, Song Z, et al. Berberine suppresses amyloid-beta-induced inflammatory response in microglia by inhibiting nuclear factor-kappaB and mitogen-activated protein kinase signalling pathways. J Pharm Pharmacol 2012; 64(10): 1510-21.
182. Yang Z, Liu Y, Yuan F, et al. Sinomenine inhibits microglia activation and attenuates brain injury in intracerebral hemorrhage. Mol Immunol 2014; 60(2): 109-14.
183. Kim M, Choi SY, Lee P, Hur J. Neochlorogenic Acid Inhibits Lipopolysaccharide-Induced Activation and Pro-inflammatory Responses in BV2 Microglial Cells. Neurochem Res 2015; 40(9): 1792-8.
184. Wang HY, Wang H, Wang JH, Wang Q, Ma QF, Chen YY. Proto-catechuic acid inhibits inflammatory responses in LPS-stimulated BV2 microglia via NF-κB and MAPKs signaling pathways. Neurochem Res 2015; 40(8): 1655-60.
185. Jin S, Park M, Song JH. (-)-Epigallocatechin-3-gallate inhibits voltage-gated proton currents in BV2 microglial cells. Eur J Pharmacol 2013; 698(1-3): 154-60.
186. Jung WK, Heo SJ, Jeon YJ, et al. Inhibitory effects and molecular mechanism of dieckol isolated from marine brown alga on COX-2 and iNOS in microglial cells. J Agric Food Chem 2009; 57(10): 4439-46.
187. Jung K, Ha E, Uhm Y, et al. Suppressive effect by Hizikia fusi-forme on the production of tumor necrosis factor in BV2 murine microglial cells. Neurol Res 2007; 29(Suppl. 1): S88-92.
188. Kang CH, Kim MJ, Seo MJ, et al. 5-Hydroxy-3,6,7,8,3‘4’-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. Food Chem Toxicol 2013; 57: 119-25.
189. Kim DC, Lee HS, Ko W, et al. Anti-inflammatory effect of meth-ylpenicinoline from a marine isolate of Penicillium sp. (SF-5995): inhibition of NF-κB and MAPK pathways in lipopolysaccharide-induced RAW264.7 macrophages and BV2 microglia. Molecules 2014; 19(11): 18073-89.
190. Mizuno T, Kuno R, Nitta A, et al. Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes. Brain Res 2005; 1066(1-2): 78-85.
191. 2, and TNF-α in BV2 microglia cells via suppression of the NF-κB pathway. Food Chem Toxicol 2011; 49(11): 2758-64.
192. Seo M, Lee JH, Baek M, et al. A novel role for earthworm peptide Lumbricusin as a regulator of neuroinflammation. Biochem Biophys Res Commun 2017; 490(3): 1004-10.
193. Zhang X, Yang Y, Du L, Zhang W, Du G. Baicalein exerts anti-neuroinflammatory effects to protect against rotenone-induced brain injury in rats. Int Immunopharmacol 2017; 50: 38-47.
194. Wang Y, Ruan W, Mi J, et al. Balasubramide derivative 3C modulates microglia activation via CaMKKβ-dependent AMPK/PGC-1α pathway in neuroinflammatory conditions. Brain Behav Immun 2018; 67: 101-17.
195. Qiu J, Wang M, Zhang J, et al. The neuroprotection of Sinomenine against ischemic stroke in mice by suppressing NLRP3 inflammasome via AMPK signaling. Int Immunopharmacol 2016; 40: 492-500.
196. Dang DK, Shin EJ, Nam Y, et al. Apocynin prevents mitochondrial burdens, microglial activation, and pro-apoptosis induced by a toxic dose of methamphetamine in the striatum of mice via inhibition of p47phox activation by ERK. J Neuroinflammation 2016; 13: 12.
197. Zhao CY, Lei H, Zhang Y, et al. L-3-n-Butylphthalide attenuates neuroinflammatory responses by downregulating JNK activation and upregulating Heme oxygenase-1 in lipopolysaccharide-treated mice. J Asian Nat Prod Res 2016; 18(3): 289-302.
198. Zeng KW, Li J, Dong X, et al. Anti-neuroinflammatory efficacy of the aldose reductase inhibitor FMHM via phospholipase C/protein kinase C-dependent NF-κB and MAPK pathways. Toxicol Appl Pharmacol 2013; 273(1): 159-71.
199. Liu Q, Chen Y, Shen C, et al. Chicoric acid supplementation prevents systemic inflammation-induced memory impairment and amyloidogenesisviainhibition of NF-κB. FASEB J 2017; 31(4): 1494-507.
200. Khan MS, Ali T, Kim MW, et al. Anthocyanins protect against LPS-induced oxidative stress-mediated neuroinflammation and neurodegeneration in the adult mouse cortex. Neurochem Int 2016; 100: 1-10.
201. Kim HS, Cho JY, Kim DH, et al. Inhibitory effects of long-term administration of ferulic acid on microglial activation induced by intracerebroventricular injection of beta-amyloid peptide (1-42) in mice. Biol Pharm Bull 2004; 27(1): 120-1.
202. Lee H, Kim YO, Kim H, et al. Flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia. FASEB J 2003; 17(13): 1943-4.
203. Anusha C, Sumathi T, Joseph LD. Protective role of apigenin on rotenone induced rat model of Parkinson’s disease: Suppression of neuroinflammation and oxidative stress mediated apoptosis. Chem Biol Interact 2017; 269: 67-79.
204. Okuyama S. [Effects of Bioactive Substances from Citrus on the Central Nervous System and Utilization as Food Material]. Ya-kugaku Zasshi 2015; 135(10): 1153-9.
205. Cui YQ, Wang Q, Zhang DM, et al. Triptolide rescues spatial memory deficits and amyloid-β aggregation accompanied by inhi- bition of inflammatory responses and MAPKs Activity in APP/PS1 transgenic mice. Curr Alzheimer Res 2016; 13(3): 288-96.
206. Hjorth E, Freund-Levi Y. Immunomodulation of microglia by docosahexaenoic acid and eicosapentaenoic acid. Curr Opin Clin Nutr Metab Care 2012; 15(2): 134-43.
207. Zhang F, Liu J, Shi JS. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol 2010; 636(1-3): 1-7.
208. Zhang F, Shi JS, Zhou H, Wilson B, Hong JS, Gao HM. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol 2010; 78(3): 466-77.
209. Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules 2010; 15(11): 7792-814.
210. Ferri P, Angelino D, Gennari L, et al. Enhancement of flavonoid ability to cross the blood-brain barrier of rats by co-administration with α-tocopherol. Food Funct 2015; 6(2): 394-400.
211. Sun D, Li N, Zhang W, et al. Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer’s disease. Colloids Surf B Biointerfaces 2016; 148: 116-29.
212. Loureiro JA, Andrade S, Duarte A, et al. Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer’s Disease. Molecules 2017; 22(2): 22.
213. Badawi GA, Abd El Fattah MA, Zaki HF, El Sayed MI. Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson’s disease. Inflammopharmacology 2017; 25(3): 369-82.
214. Łabuzek K, Liber S, Gabryel B, Okopień B. Metformin has adeno-sine-monophosphate activated protein kinase (AMPK)-independent effects on LPS-stimulated rat primary microglial cultures. Pharmacol Rep 2010; 62(5): 827-48.
215. Luo T, Wu J, Kabadi SV, et al. Propofol limits microglial activation after experimental brain trauma through inhibition of nicoti-namide adenine dinucleotide phosphate oxidase. Anesthesiology 2013; 119(6): 1370-88.
216. Chen C, Qian Y. Protective role of dexmedetomidine in unmethy-lated CpG-induced inflammation responses in BV2 microglia cells. Folia Neuropathol 2016; 54(4): 382-91.
217. Kawasaki S, Abe N, Ohtake F, et al. Effects of hypnotic bro-movalerylurea on microglial BV2 cells. J Pharmacol Sci 2017; 134(2): 116-23.
218. Hwang J, Zheng LT, Ock J, et al. Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology 2008; 55(5): 826-34.
219. Liu D, Wang Z, Liu S, Wang F, Zhao S, Hao A. Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology 2011; 61(4): 592-9.
220. Obuchowicz E, Bielecka AM, Paul-Samojedny M, Pudełko A, Kowalski J. Imipramine and fluoxetine inhibit LPS-induced activation and affect morphology of microglial cells in the rat glial culture. Pharmacol Rep 2014; 66(1): 34-43.
221. Song JH, Marszalec W, Kai L, Yeh JZ, Narahashi T. Antidepressants inhibit proton currents and tumor necrosis factor-α production in BV2 microglial cells. Brain Res 2012; 1435: 15-23.
222. Zhang F, Zhou H, Wilson BC, Shi JS, Hong JS, Gao HM. Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord 2012; 18(Suppl. 1): S213-7.
223. Hashioka S. Antidepressants and neuroinflammation: Can antidepressants calm glial rage down? Mini Rev Med Chem 2011; 11(7): 555-64.
224. Hu X, Zhou H, Zhang D, et al. Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J Neuroimmune Pharmacol 2012; 7(1): 187-201.
225. Jeon S, Kim SH, Shin SY, Lee YH. Clozapine reduces Toll-like receptor 4/NF-κB-mediated inflammatory responses through inhibition of calcium/calmodulin-dependent Akt activation in microglia. Prog Neuropsychopharmacol Biol Psychiatry 2018; 81: 477-87.
226. Jiang L, Wu X, Wang S, et al. Clozapine metabolites protect dopaminergic neurons through inhibition of microglial NADPH oxidase. J Neuroinflammation 2016; 13(1): 110.
227. Kim J, Song JH. Thioxanthenes, chlorprothixene and flupentixol inhibit proton currents in BV2 microglial cells. Eur J Pharmacol 2016; 779: 31-7.
228. Shin H, Song JH. Antipsychotics, chlorpromazine and haloperidol inhibit voltage-gated proton currents in BV2 microglial cells. Eur J Pharmacol 2014; 738: 256-62.
229. Bi W, Zhu L, Jing X, et al. Rifampicin improves neuronal apoptosis in LPS-stimulated co-cultured BV2 cells through inhibition of the TLR-4 pathway. Mol Med Rep 2014; 10(4): 1793-9.
230. Jang BC, Sung SH, Park JG, et al. Leptomycin B, a metabolite of Streptomyces, inhibits the expression of inducible nitric oxide synthase in BV2 microglial cells. Int J Oncol 2006; 29(6): 1509-15.
231. Möller T, Bard F, Bhattacharya A, et al. Critical data-based re-evaluation of minocycline as a putative specific microglia inhibitor. Glia 2016; 64(10): 1788-94.
232. Sohn MJ, Noh HJ, Yoo ID, Kim WG. Protective effect of radicicol against LPS/IFN-gamma-induced neuronal cell death in rat cortical neuron-glia cultures. Life Sci 2007; 80(18): 1706-12.
233. Okorji UP, Olajide OA. A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia. Bioorg Med Chem 2014; 22(17): 4726-34.
234. Okorji UP, Velagapudi R, El-Bakoush A, Fiebich BL, Olajide OA. Antimalarial Drug Artemether Inhibits Neuroinflammation in BV2 Microglia Through Nrf2-Dependent Mechanisms. Mol Neurobiol 2016; 53(9): 6426-43.
235. Yang MT, Lin YC, Ho WH, Liu CL, Lee WT. Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures. J Neuroinflammation 2017; 14(1): 15.
236. Dehghani F, Sayan M, Conrad A, et al. Inhibition of microglial and astrocytic inflammatory responses by the immunosuppressant my-cophenolate mofetil. Neuropathol Appl Neurobiol 2010; 36(7): 598-611.
237. Nakatani Y, Amano T, Tsuji M, Takeda H. Corticosterone suppresses the proliferation of BV2 microglia cells via glucocorticoid, but not mineralocorticoid receptor. Life Sci 2012; 91(15-16): 761-70.
238. Li Y, Hu X, Liu Y, Bao Y, An L. Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. Neuropharmacology 2009; 56(3): 580-9.
239. Liu Y, Lo YC, Qian L, et al. Verapamil protects dopaminergic neuron damage through a novel anti-inflammatory mechanism by inhibition of microglial activation. Neuropharmacology 2011; 60(2-3): 373-80.
240. Bhat SA, Goel R, Shukla R, Hanif K. Angiotensin Receptor Blockade Modulates NFκB and STAT3 Signaling and Inhibits Glial Activation and Neuroinflammation Better than Angiotensin-Converting Enzyme Inhibition. Mol Neurobiol 2016; 53(10): 6950-67.
241. Pang T, Wang J, Benicky J, Sánchez-Lemus E, Saavedra JM. Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways. J Neuroinflammation 2012; 9: 102.
242. Kim J, Song JH. Inhibitory effects of antihistamines, diphenhy-dramine and chlorpheniramine, on proton currents in BV2 microglial cells. Eur J Pharmacol 2017; 798: 122-8.
243. Song XM, Yu Q, Dong X, et al. Aldose reductase inhibitors attenuate β-amyloid-induced TNF-α production in microlgia via ROS-PKC-mediated NF-κB and MAPK pathways. Int Immunopharmacol 2017; 50: 30-7.
244. Ben-Shmuel S, Danon A, Fleisher-Berkovich S. Bradykinin decreases nitric oxide release from microglia via inhibition of cyclic adenosine monophosphate signaling. Peptides 2013; 40: 133-40.
245. Kang CH, Jayasooriya RG, Choi YH, Moon SK, Kim WJ, Kim GY. β-Ionone attenuates LPS-induced pro-inflammatory mediators such as NO, PGE2 and TNF-α in BV2 microglial cells via suppression of the NF-κB and MAPK pathway. Toxicol In Vitro 2013; 27(2): 782-7.
246. Qian L, Xu Z, Zhang W, Wilson B, Hong JS, Flood PM. Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J Neuroinflammation 2007; 4: 23.
247. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994; 269(33): 20807-10.
248. Di Lella S, Sundblad V, Cerliani JP, et al. When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry 2011; 50(37): 7842-57.
249. Funasaka T, Raz A, Nangia-Makker P. Galectin-3 in angiogenesis and metastasis. Glycobiology 2014; 24(10): 886-91.
250. Burguillos MA, Svensson M, Schulte T, et al. Microglia-Secreted Galectin-3 Acts as a Toll-like Receptor 4 Ligand and Contributes to Microglial Activation. Cell Reports 2015; S2211-1247(15)00140-0.
251. Jeon SB, Yoon HJ, Chang CY, Koh HS, Jeon SH, Park EJ. Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J Immunol 2010; 185(11): 7037-46.
252. Danella Polli C, Alves Toledo K, Franco LH, et al. Monocyte migration driven by galectin-3 occurs through distinct mechanisms involving selective interactions with the extracellular matrix. ISRN Inflamm 2013; 2013: 259256.
253. Hughes RC. Galectins as modulators of cell adhesion. Biochimie 2001; 83(7): 667-76.
254. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 1996; 93(13): 6737-42.
255. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999; 59(16): 4148-54.
256. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A, Raz A. Galectin-3, a novel binding partner of beta-catenin. Cancer Res 2004; 64(18): 6363-7.
257. Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000; 165(4): 2156-64.
258. MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008; 180(4): 2650-8.
259. Nomura K, Vilalta A, Allendorf DH, Hornik TC, Brown GC. Activated Microglia Desialylate and Phagocytose Cells via Neuramini-dase, Galectin-3, and Mer Tyrosine Kinase. J Immunol 2017; 198(12): 4792-801.
260. Sano H, Hsu DK, Apgar JR, et al. Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest 2003; 112(3): 389-97.
261. Caberoy NB, Alvarado G, Bigcas JL, Li W. Galectin-3 is a new MerTK-specific eat-me signal. J Cell Physiol 2012; 227(2): 401-7.
262. Pasquini LA, Millet V, Hoyos HC, et al. Galectin-3 drives oligodendrocyte differentiation to control myelin integrity and function. Cell Death Differ 2011; 18(11): 1746-56.
263. Boza-Serrano A, Reyes JF, Rey NL, et al. The role of Galectin-3 in α-synuclein-induced microglial activation. Acta Neuropathol Commun 2014; 2: 156.
264. Hoyos HC, Rinaldi M, Mendez-Huergo SP, et al. Galectin-3 controls the response of microglial cells to limit cuprizone-induced demyelination. Neurobiol Dis 2014; 62: 441-55.
265. Volarevic V, Milovanovic M, Ljujic B, et al. Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice. Hepatology 2012; 55(6): 1954-64.
266. Kianoush F, Nematollahi M, Waterfield JD, Brunette DM. Regulation of RAW264.7 macrophage polarization on smooth and rough surface topographies by galectin-3. J Biomed Mater Res A 2017; 105(9): 2499-509.
267. Wijesundera KK, Izawa T, Tennakoon AH, et al. M1-and M2-macrophage polarization in rat liver cirrhosis induced by thioacetamide (TAA), focusing on Iba1 and galectin-3. Exp Mol Pathol 2014; 96(3): 382-92.
268. Abreu CA, De Lima SV, Mendonça HR, Goulart CO, Martinez AM. Absence of galectin-3 promotes neuroprotection in retinal ganglion cells after optic nerve injury. Histol Histopathol 2017; 32(3): 253-62.
269. Mostacada K, Oliveira FL, Villa-Verde DM, Martinez AM. Lack of galectin-3 improves the functional outcome and tissue sparing by modulating inflammatory response after a compressive spinal cord injury. Exp Neurol 2015; 271: 390-400.
270. Lerman BJ, Hoffman EP, Sutherland ML, et al. Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Brain Behav 2012; 2(5): 563-75.
271. Chip S, Fernández-López D, Li F, Faustino J, Derugin N, Vexler ZS. Genetic deletion of galectin-3 enhances neuroinflammation, affects microglial activation and contributes to sub-chronic injury in experimental neonatal focal stroke. Brain Behav Immun 2017; 60: 270-81.
272. Krasemann S, Madore C, Cialic R, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 2017; 47: 566-81 e9.
273. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986; 44(6): 817-29.
274. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5(11): 897-907.
275. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002; 9(3): 459-70.
276. Shalini S, Dorstyn L, Dawar S, Kumar S. Old, new and emerging functions of caspases. Cell Death Differ 2015; 22(4): 526-39.
277. Galluzzi L, López-Soto A, Kumar S, Kroemer G. Caspases Connect Cell-Death Signaling to Organismal Homeostasis. Immunity 2016; 44(2): 221-31.
278. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007; 14(1): 10-22.
279. Venero JL, Burguillos MA, Brundin P, Joseph B. The executioners sing a new song: killer caspases activate microglia. Cell Death Differ 2011; 18(11): 1679-91.
280. Salvesen GS, Walsh CM. Functions of caspase 8: The identified and the mysterious. Semin Immunol 2014; 26(3): 246-52.
281. Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002; 419(6905): 395-9.
282. Kang TB, Ben-Moshe T, Varfolomeev EE, et al. Caspase-8 serves both apoptotic and nonapoptotic roles. J Immunol 2004; 173(5): 2976-84.
283. Varfolomeev EE, Schuchmann M, Luria V, et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 1998; 9(2): 267-76.
284. Burguillos MA, Deierborg T, Kavanagh E, et al. Caspase signalling controls microglia activation and neurotoxicity. Nature 2011; 472(7343): 319-24.
285. Venero JL, Burguillos MA, Joseph B. Caspases playing in the field of neuroinflammation: old and new players. Dev Neurosci 2013; 35(2-3): 88-101.
286. Dillon CP, Oberst A, Weinlich R, et al. Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Reports 2012; 1(5): 401-7.
287. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 2015; 21(7): 677-87.
288. Keller M, Rüegg A, Werner S, Beer HD. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008; 132(5): 818-31.
289. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140(6): 821-32.
290. Gurung P, Kanneganti TD. Novel roles for caspase-8 in IL-1β and inflammasome regulation. Am J Pathol 2015; 185(1): 17-25.
291. Allam R, Lawlor KE, Yu EC, et al. Mitochondrial apoptosis is dispensable for NLRP3 inflammasome activation but non-apoptotic caspase-8 is required for inflammasome priming. EMBO Rep 2014; 15(9): 982-90.
292. Kang S, Fernandes-Alnemri T, Rogers C, et al. Caspase-8 scaffolding function and MLKL regulate NLRP3 inflammasome activation downstream of TLR3. Nat Commun 2015; 6: 7515.
293. Bossaller L, Chiang PI, Schmidt-Lauber C, et al. Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner. J Immunol 2012; 189(12): 5508-12.
294. Martin-Banderas L, Holgado MA, Venero JL, Alvarez-Fuentes J, Fernández-Arévalo M. Nanostructures for drug delivery to the brain. Curr Med Chem 2011; 18(34): 5303-21.
295. Holgado MA, Venero JL, Álvarez-Fuentes J, Fernández-Arévalo M. Potential nanocarriers for brain drug delivery.Nanotechnology and drug delivery, Vol Two: Nano-Engineering Strategies and Nanomedicines against Severe Diseases 2016; 1-24.
296. Dube T, Chibh S, Mishra J, Panda JJ. Receptor targeted polymeric nanostructures capable of navigating across the blood-brain barrier for effective delivery of neural therapeutics. ACS Chem Neurosci 2017; 8(10): 2105-17.
297. Azad TD, Pan J, Connolly ID, Remington A, Wilson CM, Grant GA. Therapeutic strategies to improve drug delivery across the blood-brain barrier. Neurosurg Focus 2015; 38(3): E9.
298. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999; 36(2-3): 179-94.
299. Unicare [homepage on the Internet]. Convection Enhanced Delivery of Therapeutic Agents to the Brain. [update 2017 February 02]. Available from: https://www.unicare.com/medicalpolicies/policies/mp_pw_a05352 1.htm
300. Healy AT, Vogelbaum MA. Convection-enhanced drug delivery for gliomas. Surg Neurol Int 2015; 6(Suppl. 1): S59-67.
301. Chan KY, Jang MJ, Yoo BB, et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci 2017; 20(8): 1172-9.
302. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000; 11(1): 1-18.
303. Hanson LR, Frey WH II. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008; 9(Suppl. 3): S5.
304. Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: An excellent platform for brain targeting. Expert Opin Drug Deliv 2013; 10(7): 957-72.
305. Stützle M, Flamm J, Stefan Carle S, Schindowski K. Nose-to-Brain delivery of insulin for Alzheimer’s disease. ADMET DMPK 2015; 3: 190-202.
306. Pires A, Fortuna A, Alves G, Falcão A. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci 2009; 12(3): 288-311.
307. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012; 64(7): 614-28.
308. Adzovic L, Lynn AE, D’Angelo HM, et al. Insulin improves memory and reduces chronic neuroinflammation in the hippocampus of young but not aged brains. J Neuroinflammation 2015; 12: 63.
309. Ramos-Rodriguez JJ, Sanchez-Sotano D, Doblas-Marquez A, In-fante-Garcia C, Lubian-Lopez S, Garcia-Alloza M. Intranasal insulin reverts central pathology and cognitive impairment in diabetic mother offspring. Mol Neurodegener 2017; 12(1): 57.
310. Tiedemann LJ, Schmid SM, Hettel J, et al. Central insulin modulates food valuation via mesolimbic pathways. Nat Commun 2017; 8: 16052.
311. Brabazon F, Wilson CM, Jaiswal S, Reed J, Frey WH, Byrnes KR. Intranasal insulin treatment of an experimental model of moderate traumatic brain injury. J Cereb Blood Flow Metab 2017; 37(9): 3203-18.
312. Bell GA, Fadool DA. Awake, long-term intranasal insulin treatment does not affect object memory, odor discrimination, or reversal learning in mice. Physiol Behav 2017; 174: 104-13.
313. Malerba F, Paoletti F, Capsoni S, Cattaneo A. Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opin Drug Deliv 2011; 8(10): 1277-96.
314. Vaka SRK, Shivakumar HN, Repka MA, Murthy SN. Formulation and evaluation of carnosic acid nanoparticulate system for upregulation of neurotrophins in the brain upon intranasal administration. J Drug Target 2013; 21(1): 44-53.
315. Herran E, Igartua M, Pedraz JL, Hernandez RM. Novel drug delivery systems for releasing growth factors to the CNS: focus on Alzheimer’s and Parkinson’s diseases. Mini Rev Med Chem 2014; 14(7): 557-66.
316. Chou ML, Wu JW, Gouel F, et al. Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson’s disease. Biomaterials 2017; 142: 77-89.
317. Rodríguez Cruz Y, Strehaiano M, Rodríguez Obaya T, García Rodríguez JC, Maurice T. An intranasal formulation of erythropoietin (Neuro-EPO) prevents memory deficits and amyloid toxicity in the APPSwe transgenic mouse model of Alzheimer’s Disease. J Alzheimers Dis 2017; 55(1): 231-48.
318. Merelli A, Czornyj L, Lazarowski A. Erythropoietin: A neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy. Curr Pharm Des 2013; 19(38): 6791-801.
319. Merelli A, Czornyj L, Lazarowski A. Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases. Int J Neurosci 2015; 125(11): 793-7.
320. Danielyan L, Schäfer R, von Ameln-Mayerhofer A, et al. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res 2011; 14(1): 3-16.
321. Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-β in memory-impaired older adults. J Alzheimers Dis 2008; 13(3): 323-31.
322. Mayeux R, Schupf N. Blood-based biomarkers for Alzheimer’s disease: Plasma Aβ40 and Aβ42, and genetic variants. Neurobiol Aging 2011; 32(Suppl. 1): S10-9.
323. Bell GA, Fadool DA. Awake, long-term intranasal insulin treatment does not affect object memory, odor discrimination, or reversal learning in mice. Physiol Behav 2017; 174: 104-13.
324. Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev 2013; 65(1): 21-3.
325. Peppas NA. Historical perspective on advanced drug delivery: how engineering design and mathematical modeling helped the field mature. Adv Drug Deliv Rev 2013; 65(1): 5-9.
326. Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B 2016; 6(4): 268-86.
327. Kakkar A, Traverso G, Farokhzad OC, Weissleder R, Langer R. Nat Rev Chem 2017; •••: 1.
328. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release 2016; 235: 34-47.
329. Cetin M, Atila A, Sahin S, Vural I. Preparation and characterization of metformin hydrochloride loaded-Eudragit®RSPO and Eu-dragit®RSPO/PLGA nanoparticles. Pharm Dev Technol 2013; 18(3): 570-6.
330. Pahuja R, Seth K, Shukla A, et al. Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats. ACS Nano 2015; 9(5): 4850-71.
331. Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules 2010; 15(11): 7792-814.
332. Ferri P, Angelino D, Gennari L, et al. Enhancement of flavonoid ability to cross the blood-brain barrier of rats by co-administration with α-tocopherol. Food Funct 2015; 6(2): 394-400.
333. Sun D, Li N, Zhang W, et al. Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer’s disease. Colloids Surf B Biointerfaces 2016; 148: 116-29.
334. Loureiro JA, Andrade S, Duarte A, et al. Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer’s disease. Molecules 2017; 22(2): 1-16.
335. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009; 41(1): 40-59.
336. Mathew A, Fukuda T, Nagaoka Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS One 2012; 7(3): e32616.
337. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 2012; 161(2): 505-22.
338. Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine 2011; 6: 877-95.
339. Choi CHJ, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 2010; 107(3): 1235-40.
340. Mahajan SD, Law WC, Aalinkeel R, et al. Nanoparticle-mediated targeted delivery of antiretrovirals to the brain. Methods Enzymol 2012; 509: 41-60.
341. Gaillard PJ, Visser CC, de Boer AG. Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv 2005; 2(2): 299-309.
342. Lakhin AV, Tarantul VZ, Gening LV. Aptamers: problems, solutions and prospects. Acta Naturae 2013; 5(4): 34-43.
343. Kulbachinskiy AV. Methods for selection of aptamers to protein targets. Biochemistry (Mosc) 2007; 72(13): 1505-18.
344. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 2010; 50: 237-57.
345. Monaco I, Camorani S, Colecchia D, et al. Aptamer functionalization of nanosystems for glioblastoma targeting through the blood-brain barrier. J Med Chem 2017; 60(10): 4510-6.
346. Guo J, Gao X, Su L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011; 32(31): 8010-20.
347. Koo SH, Lee JS, Kim GH, Lee HG. Preparation, characteristics, and stability of glutathione-loaded nanoparticles. J Agric Food Chem 2011; 59(20): 11264-9.
348. Valdovinos-Flores C, Gonsebatt ME. The role of amino acid transporters in GSH synthesis in the blood-brain barrier and central nervous system. Neurochem Int 2012; 61(3): 405-14.
349. Kim GH, Kim JE, Rhie SJ, Yoon S. The Role of Oxidative Stress in Neurodegenerative Diseases. Exp Neurobiol 2015; 24(4): 325-40.
350. Acharya SR, Reddy PRV. Brain targeted delivery of paclitaxel using endogenous ligand. Asian J Pharm Sci 2016; 11: 427-38.
351. Paka GD, Ramassamy C. Optimization of curcumin-loaded PEG-PLGA nanoparticles by GSH functionalization: investigation of the internalization pathway in neuronal cells. Mol Pharm 2017; 14(1): 93-106.
352. Grover A, Hirani A, Pathak Y, Sutariya V. Brain-targeted delivery of docetaxel by glutathione-coated nanoparticles for brain cancer. AAPS PharmSciTech 2014; 15(6): 1562-8.
353. Demeule M, Régina A, Ché C, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 2008; 324(3): 1064-72.
354. Wang L, Hao Y, Li H, et al. Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: Angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles. J Drug Target 2015; 23(9): 832-46.
355. Gomes MJ, Fernandes C, Martins S, Borges F, Sarmento B. Tailoring lipid and polymeric nanoparticles as siRNA carriers towards the blood-brain barrier-from Targeting to Safe Administration. J Neuroimmune Pharmacol 2017; 12(1): 107-19.
356. Huang N, Lu S, Liu XG, Zhu J, Wang YJ, Liu RT. PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer’s disease mice. Oncotarget 2017; 8(46): 81001-13.
357. Fullstone G, Nyberg S, Tian X, Battaglia G. From the Blood to the Central Nervous System: A Nanoparticle’s Journey Through the Blood-Brain Barrier by Transcytosis. Int Rev Neurobiol 2016; 130: 41-72.
358. Loureiro JA, Gomes B, Coelho MA, do Carmo Pereira M, Rocha S. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies. Nanomedicine (Lond) 2014; 9(5): 709-22.
359. Cabezón I, Manich G, Martín-Venegas R, et al. Trafficking of gold nanoparticles coated with the 8D3 anti-transferrin receptor antibody at the mouse blood-brain barrier. Mol Pharm 2015; 12(11): 4137-45.
360. Tosi G, Costantino L, Rivasi F, et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release 2007; 122(1): 1-9.
361. Fornaguera C, Dols-Perez A, Calderó G, García-Celma MJ, Cama-rasa J, Solans C. PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier. J Control Release 2015; 211: 134-43.
362. Monsalve Y, Tosi G, Ruozi B, et al. PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting. Nanomedicine (Lond) 2015; 10(11): 1735-50.
363. Tang X, Liang Y, Zhu Y, et al. Anti-transferrin receptor-modified amphotericin B-loaded PLA-PEG nanoparticles cure Candidal meningitis and reduce drug toxicity. Int J Nanomed 2015; 10: 6227-41.
364. Carroll RT, Bhatia D, Geldenhuys W, et al. Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target 2010; 18(9): 665-74.
365. Bao H, Jin X, Li L, Lv F, Liu T. OX26 modified hyperbranched polyglycerol-conjugated poly(lactic-co-glycolic acid) nanoparticles: synthesis, characterization and evaluation of its brain delivery ability. J Mater Sci Mater Med 2012; 23(8): 1891-901.
366. Moos T, Morgan EH. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol Neurobiol 2000; 20(1): 77-95.
367. Chang J, Jallouli Y, Kroubi M, et al. Characterization of endocyto-sis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm 2009; 379(2): 285-92.
368. Kumari S, Ahsan SM, Kumar JM, Kondapi AK, Rao NM. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433). Sci Rep 2017; 7(1): 6602.
369. Hu K, Shi Y, Jiang W, Han J, Huang S, Jiang X. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson’s disease. Int J Pharm 2011; 415(1-2): 273-83.
370. Bi C, Wang A, Chu Y, et al. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment. Int J Nanomedicine 2016; 11: 6547-59.
371. Lalani J, Rathi M, Lalan M, Misra A. Protein functionalized trama-dol-loaded PLGA nanoparticles: preparation, optimization, stability and pharmacodynamic studies. Drug Dev Ind Pharm 2012;: 1-11.
372. Kumari S, Kondapi AK. Lactoferrin nanoparticle mediated targeted delivery of 5-fluorouracil for enhanced therapeutic efficacy. Int J Biol Macromol 2017; 95: 232-7.
373. Lu W, Sun Q, Wan J, She Z, Jiang XG. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 2006; 66(24): 11878-87.
374. Kesharwani P, Jain A, Jain A, et al. Cationic bovine serum albumin (CBA) conjugated poly lactic-co-glycolic acid (PLGA) nanoparticles for extended delivery of methotrexate into brain tumors. Rsc Adv 2016; 6: 89040-50.
375. Prabhakar K, Afzal SM, Surender G, Kisham V. Tween 80 containing lipid nanoemulsions for delivery of indinavir to brain. Acta Pharm Sin B 2013; 3: 345-53.
376. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release 2012; 161(2): 264-73.
377. Jain A, Jain A, Garg NK, et al. Surface engineered polymeric nanocarriers mediate the delivery of transferrin-methotrexate conjugates for an improved understanding of brain cancer. Acta Biomater 2015; 24: 140-51.
378. Jose S, Sowmya S, Cinu TA, Aleykutty NA, Thomas S, Souto EB. Surface modified PLGA nanoparticles for brain targeting of Baco-side-A. Eur J Pharm Sci 2014; 63: 29-35.
379. Yusuf M, Khan M, Khan RA, Maghrabi IA, Ahmed B. Polysor-bate-80-coated, polymeric curcumin nanoparticles for in vivo antidepressant activity across BBB and envisaged biomolecular mechanism of action through a proposed pharmacophore model. J Microencapsul 2016; 33(7): 646-55.
380. Gelperina S, Maksimenko O, Khalansky A, et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm 2010; 74(2): 157-63.
381. Martin-Banderas L, Durán-Lobato M, Muñoz-Rubio I, Alvarez-Fuentes J, Fernández-Arevalo M, Holgado MA. Functional PLGA NPs for oral drug delivery: recent strategies and developments. Mini Rev Med Chem 2013; 13(1): 58-69.
382. Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012; 4(2): 219-33.
383. Owens DE III, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307(1): 93-102.
384. J Yeh PY, Kainthan RK, Zou Y, Chiao M, Kizhakkedathu JN. Self-assembled monothiol-terminated hyperbranched polyglycerols on a gold surface: A comparative study on the structure, morphology, and protein adsorption characteristics with linear poly(ethylene glycol)s. Langmuir 2008; 24(9): 4907-16.
385. Deng Y, Saucier-Sawyer JK, Hoimes CJ, et al. The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles. Biomaterials 2014; 35(24): 6595-602.
386. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 2001; 46(1-3): 247-79.
387. Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 2010; 31(5): 908-15.
388. Huile G, Shuaiqi P, Zhi Y, et al. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with an-giopep-2 peptide and EGFP-EGF1 protein. Biomaterials 2011; 32(33): 8669-75.
389. Gao H, Qian J, Cao S, et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 2012; 33(20): 5115-23.
390. Kuo YC, Chen YC. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin-and folic acid-grafted poly(lactide-co-glycolide) nanoparticles. Int J Pharm 2015; 479(1): 138-49.
391. Loureiro JA, Gomes B, Fricker G, Coelho MAN, Rocha S, Pereira MC. Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer’s disease treatment. Colloids Surf B Biointerfaces 2016; 145: 8-13.
392. Shah L, Yadav S, Amiji M. Nanotechnology for CNS delivery of bio-therapeutic agents. Drug Deliv Transl Res 2013; 3(4): 336-51.
393. Samaridou E, Alonso MJ. Nose-to-brain peptide delivery-The potential of nanotechnology. Bioorg Med Chem 2017. pii: S0968-0896(17)31727-31733.
394. Goldsmith M, Abramovitz L, Peer D. Precision nanomedicine in neurodegenerative diseases. ACS Nano 2014; 8(3): 1958-65.
395. Pardeshi CV, Belgamwar VS, Tekade AR, Surana SJ. Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med 2013; 24(9): 2101-15.
396. Bonaccorso A, Musumeci T, Serapide MF, Pellitteri R, Uchegbu IF, Puglisi G. Nose to brain delivery in rats: Effect of surface charge of rhodamine B labeled nanocarriers on brain subregion localization. Colloids Surf B Biointerfaces 2017; 154: 297-306.
397. Sekerdag E, Lüle S, Bozdağ Pehlivan S, et al. A potential noninvasive glioblastoma treatment: Nose-to-brain delivery of farne-sylthiosalicylic acid incorporated hybrid nanoparticles. J Control Release 2017; 261: 187-98.
398. Muntimadugu E, Dhommati R, Jain A, Challa VG, Shaheen M, Khan W. Intranasal delivery of nanoparticle encapsulated taren-flurbil: A potential brain targeting strategy for Alzheimer’s disease. Eur J Pharm Sci 2016; 92: 224-34.
399. Xiao X-Y, Zhu Y-X, Bu J-Y, Li GW, Zhou JH, Zhou SP. Evaluation of neuroprotective effect of thymoquinone nanoformulation in the rodent cerebral ischemia-reperfusion model. BioMed Res Int 2016; 2016: 2571060.
400. Sharma D, Sharma RK, Bhatnagar A, et al. Nose to Brain Delivery of Midazolam Loaded PLGA Nanoparticles: In Vitro and In Vivo Investigations. Curr Drug Deliv 2016; 13(4): 557-64.